Ventripoint Diagnostics Tech To Be Used To Study Atrial Dysfunction In Children

Ventripoint Diagnostics (CSE: VPT) this morning announced the beginning of a new clinical study being conducted by the Department of Pediatrics at the University of Alberta in collaboration with both the Stollery Children’s Hospital and the Mazankowski Heart Institute. The study will be focused on children with suspected valvular disease.

More specifically, the study is to measure atrial volumes and ejection fractions in children suspected of having the disease. Using the firms proprietary tech, the VMS+ 3.0, the company will look to provide a reliable, accurate and simple procedure to assess the function of valves between the atria and ventricles of the heart. If successful, the tech will be able to provide regular monitoring of children through their early years as the heart grows.

The study will look to demonstrate the abilities of the tech with respect to evaluating the performance and function of the left and right atria in combination with an assessment of the ventricle. The study will also see the assessment by 3D ultrasound and MRI where possible to serve as a comparison.

“Ventripoint is pleased to sponsor this study to further show how repeated rapid assessment of pediatric patients using 2D ultrasound can assist in therapeutic decisions. 3D echocardiography is often unreadable and MRI procedures are too expensive and arduous to perform frequently as the child grows.”

George Adams, CEO of Ventripoint Diagnostics

The enlargement of the left atrial is an indicator of a number of potential conditions, which leads to a risk factor for atrial arrhythmias. Right atrial volume is also a known indicator for right ventricular diastolic dysfunction, among other conditions. The early diagnosis of such conditions is ideal in terms of providing therapeutic interventions.

Ventripoint Diagnostics last traded at $0.415 on the CSE.

FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply